NCT01707472View on ClinicalTrials.gov

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

October 4, 2012

Primary Completion Date

October 17, 2014

Study Completion Date

October 17, 2014

Conditions

Liver FibrosisHepatitis CHIVHIV/HCV Co-infection

Interventions

BIOLOGICAL

Simtuzumab

700 mg intravenously for a total of 12 infusions.

Trial Locations (1)

20892

NIH Department of Laboratory Medicine, Bethesda

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Gilead Sciences

INDUSTRY